What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cytokine
- Immune system
Ravinder Nath Maini mostly deals with Tumor necrosis factor alpha, Rheumatoid arthritis, Internal medicine, Cytokine and Immunology.
His studies in Rheumatoid arthritis integrate themes in fields like Infliximab and Arthritis.
Ravinder Nath Maini has researched Infliximab in several fields, including Placebo, Surgery and Rheumatology.
The study incorporates disciplines such as Gastroenterology and Endocrinology in addition to Internal medicine.
Ravinder Nath Maini has included themes like Inflammation and Synovial membrane in his Cytokine study.
Ravinder Nath Maini is studying Monoclonal antibody, which is a component of Immunology.
His most cited work include:
- Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2688 citations)
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha (1003 citations)
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis (652 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Immunology, Rheumatoid arthritis, Tumor necrosis factor alpha, Antibody and Arthritis.
Rheumatoid arthritis is a primary field of his research addressed under Internal medicine.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Endocrinology.
His work carried out in the field of Tumor necrosis factor alpha brings together such families of science as Inflammation, Receptor, Cancer research and Necrosis.
His Arthritis research incorporates elements of Peripheral blood mononuclear cell and Autoimmune disease.
His study in Infliximab is interdisciplinary in nature, drawing from both Clinical trial and Surgery.
He most often published in these fields:
- Immunology (56.15%)
- Rheumatoid arthritis (43.08%)
- Tumor necrosis factor alpha (28.46%)
What were the highlights of his more recent work (between 2001-2020)?
- Rheumatoid arthritis (43.08%)
- Surgery (13.08%)
- Immunology (56.15%)
In recent papers he was focusing on the following fields of study:
Rheumatoid arthritis, Surgery, Immunology, Infliximab and Internal medicine are his primary areas of study.
His Rheumatoid arthritis study integrates concerns from other disciplines, such as Methotrexate and Anti-TNF therapy.
His Surgery study combines topics in areas such as Infliximab therapy and Early rheumatoid arthritis.
His study in Cytokine, Antibody, Arthritis and Tumor necrosis factor alpha is carried out as part of his studies in Immunology.
His work in Infliximab covers topics such as Early ra which are related to areas like Joint destruction, Vascularity and VEGF receptors.
The Internal medicine study combines topics in areas such as Gastroenterology and Placebo.
Between 2001 and 2020, his most popular works were:
- Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate (449 citations)
- Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. (389 citations)
- Infliximab in active early rheumatoid arthritis (207 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Immune system
- Cytokine
Ravinder Nath Maini focuses on Rheumatoid arthritis, Immunology, Infliximab, Cytokine and Arthritis.
Many of his studies on Immunology involve topics that are commonly interrelated, such as Hamster.
His Infliximab research is multidisciplinary, incorporating elements of Placebo, Methotrexate, Surgery and Rheumatology.
His Methotrexate research includes elements of Gastroenterology and Connective tissue disease.
His Cytokine research includes themes of Tumor necrosis factor alpha, Synovial Cell, Synovial membrane, Synovial fluid and Transforming growth factor beta.
Ravinder Nath Maini studied Arthritis and Randomized controlled trial that intersect with Pharmacotherapy and Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
